Inozyme Pharma (ITOS) Upgraded by Zacks Investment Research to Buy

Inozyme Pharma} stock has undergone multiple analysts rating changes in the recent past.  Inozyme Pharma Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Inozyme Pharma (ITOS) Upgraded by Zacks Investment Research to Buy